.Pharmacolibrary.Drugs.ATC.B.B06AA03 .Pharmacolibrary.Drugs.ATC.B.B06AA03| name: | Hyaluronidase |
| ATC code: | B06AA03 | route: | subcutaneous |
| n-compartments | 1 |
Hyaluronidase is an enzyme that depolymerizes hyaluronic acid, a constituent of the extracellular matrix. It is used to enhance the absorption and dispersion of other injected drugs, improve resorption of radiopaque agents in subcutaneous urography, and in the management of extravasation as well as ophthalmic surgery to facilitate tissue penetration. Hyaluronidase is approved and in clinical use today.
No published peer-reviewed pharmacokinetic models are available for hyaluronidase in humans. Available data suggest very rapid inactivation following subcutaneous administration, believed to be mainly via tissue and plasma proteases. These estimates are based on indirect and non-quantitative data.
Tan, AR, et al., & Jackisch, C (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. The Lancet. Oncology 22(1) 85–97. DOI:10.1016/S1470-2045(20)30536-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33357420
Li, Z, et al., & Yel, L (2024). Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies. International immunopharmacology 128 111447–None. DOI:10.1016/j.intimp.2023.111447 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38185032
Mateos, MV, et al., & Usmani, SZ (2020). Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. The Lancet. Haematology 7(5) e370–e380. DOI:10.1016/S2352-3026(20)30070-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32213342